EGFR and non-small cell lung carcinoma: The additive effect of ZM used in combination with Erlotinib in the H3255 and H1975 cell lines suggests that combined inhibition of the VEGFR-2 and EGFR pathways may be an effective treatment method in NSCLC patients with EGFR mutations.